By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eiger Biopharma 

Palo Alto  California    U.S.A.
Phone: n/a Fax: n/a


Start Up

Company News
Eiger Biopharma Announces Acquisition Of Exclusive License To Program For Treatment Of Post-Bariatric Hypoglycemia From Stanford University 11/12/2015 7:49:43 AM
Eiger Biopharma Announces Acquisition Of Exclusive License To Lymphedema Program From Stanford University 11/11/2015 6:39:09 AM
Eiger Biopharma Announces Acquisition Of Exclusive License To Pulmonary Arterial Hypertension (PAH) Program From Stanford University 11/10/2015 6:19:39 AM
Eiger Biopharma Announces License Agreement With Nippon Kayaku Co., Ltd. To Develop Bestatin (ubenimex) For Inflammatory Diseases Involving LTB4 11/9/2015 7:22:26 AM
Eiger Biopharma Appoints Thomas J. Dietz, Ph.D. To The Eiger Board Of Directors 10/22/2015 11:36:36 AM
Eiger Biopharma Appoints Eduardo Martins, M.D., Ph.D., As Senior Vice President, Liver And Infectious Diseases Drug Development 10/20/2015 11:29:04 AM
Eiger Biopharma Announces Key Operational Hires To Senior Management Team: Jim Welch, Chief Financial Officer; Jim Shaffer, Chief Business Officer 8/17/2015 7:28:07 AM
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015 8:14:32 AM
FDA Grants Fast Track Designation To Eiger Biopharma's Lonafarnib For Hepatitis Delta Virus (HDV) Infection 4/20/2015 11:02:46 AM
Eiger Biopharma Announces Senior Staff Appointments In Clinical Development And Regulatory Affairs: 4/14/2015 6:54:49 AM